28. - 30.09.2022 | The 60th Annual Meeting of the Biophysical Society of Japan
Conference Venue:
Hakodate Arena / Hakodate Citizen Hall (Hybrid)
1-32-2 Yunokawa-cho
Hakodate 042-0932
Japan
Go to the Conference website here.
25. - 28.09.2022 | German Biophysical Society Meeting 2022
Conference Venue:
University of Konstanz
Universitätsstrasse 10, 78464
Konstanz, Germany
Go to the Conference website here.
15. - 16.09.2022 | The 1st Assay Ready Cells user group meeting
Conference Venue:
acCELLerate GmbH
Osterfeldstraße 12-14
Hamburg, Germany
Go to the Conference website here.
19. - 21.09.2022 | Biomembrane Days 2022
Conference Venue:
Harnack Haus
Ihnestrasse 16-20, 14195
Berlin, Germany
Go to the Conference website here.
15. - 18.09.2022 | Europhysiology 2022
Conference Venue:
Tivoli Hotel & Congress Center
Arni Magnussons Gade 2, 1577
Copenhagen, Denmark
Go to the Conference website here.
11. - 14.09.2022 | Safety Pharmacology Society 2022 Annual Meeting
Conference Venue:
Palais des congrès de Montréal
Montréal, Québec, CAN
Go to the Conference website here.
Meet Rodolfo, Ron, Sonja, Wyatt and Brian
Nanion Chief Operating Officer, Rodolfo J. Haedo, Account Executive, Ron Knox, Director of Scientific Affairs, Sonja Stölzle-Feix, Director of Sales - North America, Wyatt Hall and Marketing Associate, Brian Camillo will be in attendance.
Join them at booth #710
Partner Talk: Comprehensive Models for Assessing Drug-Induced Cardio- and Hepatotoxicity
Hosts: Nanion Technologies GmbH and FUJIFILM Cellular Dynamics, Inc.
Time: Tuesday, September 13th at 12:00 - 1:00 pm
Room: 519 A
Session Description:
This joint partner session will focus on the characterization of drug effects on human induced pluripotent stem cell-derived (hiPSC-derived) cardiomyocytes and hepatocytes. The use of these cell models continues to increase in the assessment of cardiac safety and toxicological side effects of newly developed compounds, due to their reproducibility and low ethical concern.
However, the obstacles derived from using a 2D culture setting, immature phenotype, or serum-containing media for chronic assays raise concerns over non-physiological responses in preclinical drug development and safety. Here, we will introduce solutions to these hurdles by using innovative pro-maturation technologies, specialized cell culture conditions and newly developed recording protocols. Characterization, pro-maturation and toxicity assays using iCell Cardiomyocytes2 for automated patch clamp (Patchliner Dynamite8) and contractile force recordings (FLEXcyte 96) will be presented.
Furthermore, data highlighting acute and chronic effects of metabolically active hepatotoxic compounds (Aflatoxin B1) will be shown in standard 2D conditions using an impedance-based, non-invasive assay (CardioExcyte 96), indicating that the iCell Hepatocytes are metabolically active and functional.
Poster Sessions
Poster # SP011
Poster Title: Reliable Identification of Cardiac Liability in Drug Discovery Using Automated Patch Clamp III: Best Practices for Cav1.2 Current in a High Throughput Screening Environment
Presenter: Dr. Sonja Stölzle-Feix
Poster # SP035 [Additionally This poster has also been chosen for a Rapid Fire presentation on Tuesday, September 13, 2022 1:40‐1:45 PM, Sonja Stölzle-Feix]
Poster Title: Disease Modeling Utilizing Human Pluripotent Stem Cell-Derived Cardiomyocytes and Physiological Characterization
Presenter: Dr. Sonja Stölzle-Feix
Poster # SP036
Poster Title: Comprehensive impedance-based hepatotoxicity assay for metabolically active iPSC-derived hepatocytes
Presenter: Ronald Knox
Poster # SP103
Poster Title: Reliable and Straightforward Cardiac Safety Liability and Proarrhythmic Assessment developed using Automated Patch Clamp
Presenter: Rodolfo Haedo
About the Safety Pharmacology Society
Mission
The Society will lead the global safety pharmacology community in the development and safe medical use of biologically active molecular entities. We will achieve this vision by bridging across disciplines to predict, identify, characterize, monitor, and mitigate potentially undesirable pharmacodynamic activities in nonclinical studies and guiding their translation into clinical trials and beyond, to benefit all patients.
Vision
The Society will lead the global safety pharmacology community in the development and safe medical use of biologically active molecular entities. We will achieve this vision by bridging across disciplines to predict, identify, characterize, monitor, and mitigate potentially undesirable pharmacodynamic activities in nonclinical studies and guiding their translation into clinical trials and beyond, to benefit all patients.
Learn More
About the Canadian Society of Pharmacology and Therapeutics
The Canadian Society of Pharmacology and Therapeutics (CSPT) is a national not-for-profit charitable organization that aims to foster the application of educational and research excellence to drug discovery and therapeutic choice.
CSPT is recognized for its involvement with the Royal College of Physicians and Surgeons of Canada fellowship training program in Clinical Pharmacology and Toxicology, as well its support of graduate/postdoctoral trainees and academic researchers across the country.
CSPT is the official Canadian member of the International Union of Basic and Clinical Pharmacology (IUPHAR).
Learn more